Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Social Psychiatry and Psychiatric Epidemiology
Published in: Social Psychiatry and Psychiatric Epidemiology 2/2009

01-02-2009 | ORIGINAL PAPER

Outcome study of first-episode schizophrenia in a developing country: quality of life and antipsychotics

Author: Kok Yoon Chee, MD (USM) MMED (Psych) (UM)

Published in: Social Psychiatry and Psychiatric Epidemiology | Issue 2/2009

Login to get access

Abstract

Aim

Quality of life has recently been emphasized in the management of schizophrenia, yet data from developing country is lacking. We explored the differences in subjective quality of life between conventional antipsychotics (CAs) and atypical antipsychotics (AAs).

Methods

This is a naturalistic study conducted in Kuala Lumpur, Malaysia. Patients with first-episode schizophrenia and related psychosis were recruited from Kuala Lumpur Hospital. WHOQOL-BREF, side effects of medications and other variables were assessed after 1 year of treatment in routine clinical situation.

Results

The study comprised 120 adults. There were no significant statistical differences between groups concerning subjective quality of life, extrapyramidal side effects and employment. Significant less benzhexol usage was reported among AAs (P < 0.001) compared to CAs and sulpiride.

Conclusion

Patients treated with CAs, sulpiride or AAs experienced similar quality of life, clinical and health outcomes after 1 year commencing treatment. Overall, the results are in line with other major pragmatic clinical trials. This study also found sulpiride cost-effective.
Literature
1.
Amin S et al (1999) Evaluating the health of the nation outcome scales: reliability and validity in a three-year follow-up of first-onset psychosis. Br J Psychiatry 174:399–403PubMedCrossRef
2.
3.
Bradford LD (2005) The ethnopharmacology of atypical antipsychotics, CNS Spectr 10 (2005) (3 Suppl. 2):S6–S12
4.
Chan CH et al (1997) Hong Kong Chinese Version WHOQOL-108 and its BREF form. In: Quality of life symposium. Hong Kong Polytechnic University, Hong Kong
5.
Chaudhry HR, Kongsakon R et al (2003) Quality of life and clinical outcomes for Asian outpatients with schizophrenia: a double-blind randomized comparison of olanzapine and haloperidol. J Eur College Neuropsychopharm 13(4):S309CrossRef
6.
Cohen J (1988) Statistical power analysis for the behavioral sciences. 2nd, Lawrence Earlbaum Associates, Hillsdale
7.
Geddes J et al (2000) Atypical antipsychotics in the treatment of schizophrenia: systemic overview and meta-regression analysis. BMJ 321:1371–1376PubMedCrossRef
8.
Gerlach J, Behnke K, Heltberg J, Munk-Anderson E, Nielsen H (1985) Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. Br J Psychiatry 147:283–288PubMedCrossRef
9.
Hasanah CI et al (2003) World Health Organization Quality of Life Assessment; Brief Version in Bahasa Malaysia. Malaysia Med J 58:79–88
10.
Härnryd C, Bjerkenstedt L, Björk K et al (1984) Clinical evaluation of sulpiride in schizophrenic patients—a double-blind comparison with chlorpromazine. Sulpiride in schizophrenic. Acta Psychiatr Scand 69(s311):7–30CrossRef
11.
Jones PB et al (2006) Randomized controlled trial of the effect on quality of life of second- vs. first- generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1087PubMedCrossRef
12.
Kulkarni A, Adams A, Corteling N et al (2000) Sex differences in the quality of life of people with schizophrenia. Schizophr Res 41(1):58–59CrossRef
13.
Leung KF et al (1997) Cultural relevancy of WHOQOL structure in Hong Kong Chinese. Quality of Life Symposium. Hong Kong Polytechnic University, Hong Kong
14.
Leung A, Chua P (2000) Sex differences in schizophrenia,a review of the literature. Acta Psychiatr Scand 101:3–38CrossRef
15.
Lieberman JA et al (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396–1404PubMedCrossRef
16.
Lieberman JA et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med 353(12):1209–1223CrossRef
17.
Lin KM, Finder E (1983) Neuroleptic dosage for Asians. Am J Psychiatry 140:490–491PubMed
18.
Lin KM, Poland RE, Nuccio I (1989) A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry 146(10):1307–1311PubMed
19.
Marwaha S, Johnson S, Bebbington P et al (2007) Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. Br J Psychiatry 191:30–37PubMedCrossRef
20.
Ministry Of Health (2004) Malaysian burden of disease and injury study: health prioritization: burden of disease approach. Division of Burden of Disease, Institute of Public Health: Ministry of Health, Malaysia
21.
Mubarak AR (2005) Social functioning and quality of life of people with schizophrenia in the northern region of Malaysia. Australian e-Journal for the Advancement of the Mental Health 4(3)
22.
Mueser KT, McHugo GJ, Curran PJ (1997) Factor structure of the brief psychiatric rating scale in schizophrenia. Psychol Assess 9:196–204CrossRef
23.
National Economy Planning Unit (2005) Selangor
24.
National Mental Health Registry (2005) National Mental Health Registry’s: Report 2003–2004. Ministry of Health, Malaysia
25.
Rosenheck R et al (2003) Effectiveness and cost of olanzapine and haloperidol in treatment of schizophrenia: a randomized controlled trial. JAMA 290:2693–2702PubMedCrossRef
26.
Rosenheck R, Leslie D, Keefe R et al (2006) Barriers to employment for people with Schizophrenia. Am J Psychiatry 163(3):411–417PubMedCrossRef
27.
Rummel C et al. (2006) New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst. Rev. 4th Quarter
28.
Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2:e141PubMedCrossRef
29.
Sameerah SAR, Sarojini S (eds) (2007) Malaysian Statistics on Medicine 2005, Kuala Lumpur
30.
Schooler N et al (2005) Risperidone and haloperidol in first-episode psychosis: a long term randomized trial. Am J Psychiatry 162:947–953PubMedCrossRef
31.
Simpson G, Angus J (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11–19CrossRef
32.
Skevington SM, Lotfy M, O’Connell KA (2004) The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A Report from the WHOQOL Group. Qual Life Res 13:299–310PubMedCrossRef
33.
Soares BGO, Fenton M, Chue P (2008) Sulpiride for schizophrenia. Cochrane Schizophrenia Group Cochrane Database of Systematic Reviews, 2
34.
Stroup TS et al (2003) The national institute of mental health clinical antipsychotic trials of intervention effectiveness (CATIE) project. Schizophr Bull 29(1):15–31PubMed
35.
Swartz MS et al (2007) Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 164:428–430PubMedCrossRef
36.
The WHOQOL Group (1998) Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 28:551–558CrossRef
37.
Tan HY, Choo WC et al (2004) A community study of the health-related quality of life of schizophrenia and general practice outpatients in Singapore. Soc Psychiatry Psychiatr Epidemiol 39:106–112PubMedCrossRef
38.
The WHOQOL Group (1995) The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 41:1403–1409CrossRef
39.
Wing J et al (1998) Health of the Nation Outcome Scales (HoNOS): Research and development. Br J Psychiatry 172:11–18PubMedCrossRef
Metadata
Title
Outcome study of first-episode schizophrenia in a developing country: quality of life and antipsychotics
Author
Kok Yoon Chee, MD (USM) MMED (Psych) (UM)
Publication date
01-02-2009
Publisher
D. Steinkopff-Verlag
Published in
Social Psychiatry and Psychiatric Epidemiology / Issue 2/2009
Print ISSN: 0933-7954
Electronic ISSN: 1433-9285
DOI
https://doi.org/10.1007/s00127-008-0415-0

Other articles of this Issue 2/2009

Social Psychiatry and Psychiatric Epidemiology 2/2009 Go to the issue

ORIGINAL PAPER

Five-year mortality of Finnish schizophrenia patients in the era of deinstitutionalization

ORIGINAL PAPER

Hallucinations in visually impaired individuals

ORIGINAL PAPER

Mental disorders of male parricidal offenders

ORIGINAL PAPER

Mexican American caregivers’ coping efficacy

ORIGINAL PAPER

Practice patterns and treatment choices among psychiatrists in New Delhi, India

ORIGINAL PAPER

Psychiatric history modifies the gender ratio of suicide: an East and West comparison